
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with... Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.037 | 4.33814046195 | 0.8529 | 0.94 | 0.7548 | 543009 | 0.85515463 | CS |
4 | 0.1911 | 27.3468803663 | 0.6988 | 1.03 | 0.493 | 2402257 | 0.93065679 | CS |
12 | 0.1899 | 27.1285714286 | 0.7 | 1.03 | 0.493 | 883255 | 0.90892536 | CS |
26 | 0.1399 | 18.6533333333 | 0.75 | 1.5 | 0.493 | 484479 | 0.91756566 | CS |
52 | -0.7201 | -44.7267080745 | 1.61 | 3.25 | 0.493 | 383872 | 1.14838157 | CS |
156 | -3.4101 | -79.3046511628 | 4.3 | 4.3 | 0.45 | 223850 | 1.20660635 | CS |
260 | -4.3001 | -82.8535645472 | 5.19 | 30.2 | 0.45 | 472718 | 12.85712108 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.